|
Torsades de Pointes
|
0.500 |
Biomarker
|
disease |
BEFREE |
Her ECG revealed QT-prolongation associated with LQT2-specific T-U wave patterns, T wave alternans, long QT-dependent torsade de pointes (TdP) and ventricular fibrillation (VF).
|
29037423 |
2019 |
|
Torsades de Pointes
|
0.500 |
Biomarker
|
disease |
BEFREE |
However, typical cases of Torsade de pointes occurred in association with AV block and LQT2.
|
29929706 |
2018 |
|
Torsades de Pointes
|
0.500 |
Biomarker
|
disease |
BEFREE |
In long QT syndrome type 2 (I<sub>Kr</sub> blockade or bradycardia), the higher Ca<sup>2+</sup> influx via I<sub>Ca,L</sub> causes Ca<sup>2+</sup> overload, spontaneous sarcoplasmic reticulum Ca<sup>2+</sup> release, and reactivation of I<sub>Ca,L</sub> that triggers early afterdepolarizations and torsades de pointes.
|
29330129 |
2018 |
|
Torsades de Pointes
|
0.500 |
Biomarker
|
disease |
BEFREE |
A systematic review was performed to categorize the hERG (human ether-a-go-go-related gene) liability of antihistamines, antipsychotics, and anti-infectives and to compare it with current clinical risk of torsade de pointes (TdP).
|
28019033 |
2017 |
|
Torsades de Pointes
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We describe a case of torsade de pointes (TdP) caused by sevoflurane in a patient with c-LQTS genotype 2 (LQT2).
|
27555138 |
2016 |
|
Torsades de Pointes
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We identified the KCNH2-H562R mutation in a 65-year-old man with a prolonged QTc interval who had experienced an episode of torsade de pointes.
|
25819988 |
2015 |
|
Torsades de Pointes
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The blockade of the human ether-a-go-go-related gene (HERG) channel is a major concern for QT prolongation and Torsade de Pointes risk.
|
23103500 |
2013 |
|
Torsades de Pointes
|
0.500 |
Biomarker
|
disease |
BEFREE |
A greater instability of most aspects of VR already at rest seems to be a salient feature in both LQT1 and LQT2, which might pave the way for early afterdepolarizations and torsades de pointes ventricular tachycardia.
|
23643511 |
2013 |
|
Torsades de Pointes
|
0.500 |
Biomarker
|
disease |
BEFREE |
Four fetuses (2 KCNH2 and 2 SCN5A), all with corrected QT ≥ 620 ms, had frequent episodes of Torsade de Pointes, which were present 22-79% of the time.
|
24218437 |
2013 |
|
Torsades de Pointes
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Thus, patients with an acute MI carrying the KCNH2-K897T polymorphism had an 8-fold greater risk of experiencing TdP compared with controls (95% confidence interval = 2-40).
|
22338672 |
2012 |
|
Torsades de Pointes
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The level of inhibition of the human Ether-à-go-go-related gene (hERG) channel is one of the earliest preclinical markers used to predict the risk of a compound causing Torsade-de-Pointes (TdP) arrhythmias.
|
21300721 |
2011 |
|
Torsades de Pointes
|
0.500 |
Biomarker
|
disease |
CTD_human |
Block of the human Ether-a-go go Related Gene (hERG) ion channel in particular is associated with life-threatening arrhythmias, such as Torsade de Pointes (TdP).
|
20034863 |
2010 |
|
Torsades de Pointes
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The main mechanism of QT prolongation and TdP is block of the rapid component of the cardiac delayed rectifier K(+) current (I(Kr)), which is encoded by hERG (human ether-à-go-go-related gene).
|
20467834 |
2010 |
|
Torsades de Pointes
|
0.500 |
Biomarker
|
disease |
BEFREE |
The main mechanism underlying an acquired QT syndrome and a potentially fatal arrhythmia called torsades de pointes is the inhibition of potassium channel encoded by hERG (the human ether-a-go-go-related gene).
|
18988205 |
2009 |
|
Torsades de Pointes
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
KCNQ1 and KCNH2 are the two most common potassium channel genes causing long QT syndrome (LQTS), an inherited cardiac arrhythmia featured by QT prolongation and increased risks of developing torsade de pointes and sudden death.
|
18808722 |
2008 |
|
Torsades de Pointes
|
0.500 |
Biomarker
|
disease |
BEFREE |
Pause dependence of TdP onset is predominant in LQT2 but absent or rare in LQT1.
|
17088455 |
2006 |
|
Torsades de Pointes
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A likely mechanism for QT interval prolongation and TdP arrhythmias is blockade of the rapid component of the cardiac delayed rectifier K+ current (IKr), which is encoded by human ether-a-go-go-related gene (HERG).
|
16647758 |
2006 |
|
Torsades de Pointes
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The most common problem is acquired long QT syndrome caused by drugs that block human ether-a-go-go-related-gene (hERG) K(+) channels, delay cardiac repolarization and increase the risk of torsades de pointes arrhythmia (TdP).
|
15749156 |
2005 |
|
Torsades de Pointes
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
High concentrations of intravenous nicorandil, a potassium channel opener, have been shown to be capable of decreasing QT and TDR, and preventing TdP in LQT1 and LQT2 but not in LQT3.
|
15892662 |
2005 |
|
Torsades de Pointes
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
KCNH2 codes for the HERG ion channel and mutations in the gene are associated with congenital long-QT syndrome (LQTS), and in the family of this case of SIDS, the mutation was associated with Torsades de pointes tachycardia, making SIDS the most likely outcome of congenital LQTS.
|
15670565 |
2005 |
|
Torsades de Pointes
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Rare mutations in KCNH2 provide the pathogenic substrate for type 2 congenital long QT syndrome (LQTS), thus placing this cardiac potassium channel squarely in the intersection between congenital LQTS (the "Rosetta stone" of the heritable channelopathies) and acquired LQTS (drug-induced TdP).
|
16253929 |
2005 |
|
Torsades de Pointes
|
0.500 |
Biomarker
|
disease |
CTD_human |
Mechanisms of arsenic-induced prolongation of cardiac repolarization.
|
15213294 |
2004 |
|
Torsades de Pointes
|
0.500 |
Biomarker
|
disease |
BEFREE |
Putative interactions between the Human Ether-a-go-go Related Gene (HERG), QT interval prolongation and Torsades de Pointes (TdP) are now integral components of any discussion on drug safety.
|
15464027 |
2004 |
|
Torsades de Pointes
|
0.500 |
Biomarker
|
disease |
LHGDN |
To determine what role genetic variation in the hERG gene plays in drug-induced arrhythmias, we screened DNA samples collected from 105 atrial-fibrillation patients treated with dofetilide for polymorphisms, seven of whom developed TdP.
|
15522280 |
2004 |
|
Torsades de Pointes
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A decrease of IKr or IKs by mutations in either HERG, KvLQT1, or KCNE family results in inherited long QT syndrome (LQTS) with high risk for Torsades de pointes (TdP)-type polymorphic ventricular tachycardia and ventricular fibrillation.
|
14769199 |
2004 |